Kidney Cancer News and Research

RSS
Kidney cancer is usually defined is a cancer that originates in the kidney. The two most common types of kidney cancer, reflecting their location within the kidney, are renal cell carcinoma (RCC) and urothelial cell carcinoma (UCC) of the renal pelvis.
Onyx Pharmaceuticals acquires Proteolix

Onyx Pharmaceuticals acquires Proteolix

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Onyx Pharmaceuticals to present data on carfilzomib and ONX 0803 at the 51st ASH Annual Meeting

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Third-quarter 2009 financial results of Antigenics announced

Third-quarter 2009 financial results of Antigenics announced

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

New urine tests may help predict kidney problems post surgery

New urine tests may help predict kidney problems post surgery

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

EMEA informs Antigenics on a negative opinion for Oncophage MAA

EMEA informs Antigenics on a negative opinion for Oncophage MAA

FDA approves new oral medication for renal cell carcinoma

FDA approves new oral medication for renal cell carcinoma

Policymakers urged to preserve access to advanced imaging in final health care reform legislation

Policymakers urged to preserve access to advanced imaging in final health care reform legislation

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

FDA's Oncologic Drugs Advisory Committee recommends approval of GlaxoSmithKline's VOTRIENT

FDA's Oncologic Drugs Advisory Committee recommends approval of GlaxoSmithKline's VOTRIENT

Fifth SEEM anniversary meeting to be held in Belgrade

Fifth SEEM anniversary meeting to be held in Belgrade

Memorial Sloan-Kettering Cancer Center awards $50,000 to three young investigators

Memorial Sloan-Kettering Cancer Center awards $50,000 to three young investigators

Winners of Paul Marks Prize 2009

Winners of Paul Marks Prize 2009

Phase 2 clinical trial results of IMO-2055 announced

Phase 2 clinical trial results of IMO-2055 announced

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

Phase 2 trial results of Bayer's Nexavar in combination with capecitabine announced

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

Phase 1b interim clinical trial results of IMO-2055, Tarceva and Avast combination announced

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.